Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation

References

• Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, Jaffe ES. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–12. doi:10.1182/blood-2018-11-881268.
   PubMed Web of Science ®Google Scholar
• Mangold AR, Thompson AK, Davis MD, Saulite I, Cozzio A, Guenova E, Hodak E, Amitay-Laish I, Pujol RM, Pittelkow MR, et al. Early clinical manifestations of Sezary syndrome: A multicenter retrospective cohort study. J Am Acad Dermatol. 2017;77(4):719–727. doi:10.1016/j.jaad.2017.05.036.
   PubMed Web of Science ®Google Scholar
• Molloy K, Jonak C, Woei AJF, Guenova E, Busschots AM, Bervoets A, Hauben E, Knobler R, Porkert S, Fassnacht C, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020;182(3):770–779. doi:10.1111/bjd.18089.
   Web of Science ®Google Scholar
• Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 2010;116(5):767–771. doi:10.1182/blood-2009-11-251926.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Prince HM, Vermeer MH, Quaglino P, Horwitz S, Porcu P, Stadler R, Wood GS, Beylot-Barry M, Pham-Ledard A, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and sezary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766–3773. doi:10.1200/JCO.2015.61.7142.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, et al. The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients. Br J Dermatol. 2018;181(2):350–357. doi:10.1111/bjd.17258.
   Web of Science ®Google Scholar
• Guenova E, Ignatova D, Chang YT, Contassot E, Mehra T, Saulite I, Navarini A, Mitev V, Dummer R, Kazakov D, et al. Expression of CD164 on malignant T cells in Sézary syndrome. Acta Derm Venereol. 2016;96(4):464–467. doi:10.2340/00015555-2264.
   PubMed Web of Science ®Google Scholar
• Saulite I, Hoetzenecker W, Weidinger S, Cozzio A, Guenova E, Wehkamp U. Sezary syndrome and atopic dermatitis: comparison of immunological aspects and targets. Biomed Res Int. 2016;2016:9717530. doi:10.1155/2016/9717530.
   PubMed Web of Science ®Google Scholar
• Argnani L, Broccoli A, Zinzani PL. Cutaneous T-cell lymphomas: focusing on novel agents in relapsed and refractory disease. Cancer Treat Rev. 2017;61:61–69. doi:10.1016/j.ctrv.2017.10.007.
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. Cancer Immuno Sci. 2013;342:1432–1433.
   Google Scholar
• Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib Study. J Clin Oncol. 2016;34(23):2698–2704. doi:10.1200/JCO.2015.65.9789.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer–response. Clin Cancer Res. 2013;19(19):5542. doi:10.1158/1078-0432.CCR-13-2234.
   PubMed Web of Science ®Google Scholar
• Xia Y, Medeiros LJ, Young KH. Immune checkpoint blockade: releasing the brake towards hematological malignancies. Blood Rev. 2016;30(3):189–200. doi:10.1016/j.blre.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Gianchecchi E, Delfino DV, Fierabracci A. Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. Autoimmun Rev. 2013;12(11):1091–1100. doi:10.1016/j.autrev.2013.05.003.
   PubMed Web of Science ®Google Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236(1):219–242. doi:10.1111/j.1600-065X.2010.00923.x.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation. Sci Signal. 2012;5(230):ra46. doi:10.1126/scisignal.2002796.
   PubMed Web of Science ®Google Scholar
• Getts DR, Turley DM, Smith CE, Harp CT, McCarthy D, Feeney EM, Getts MT, Martin AJ, Luo X, Terry RL, et al. Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells. J Immunol. 2011;187(5):2405–2417. doi:10.4049/jimmunol.1004175.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Feldman AL, Wada DA, Yang -Z-Z, Comfere NI, Dong H, Kwon ED, Novak AJ, Markovic SN, Pittelkow MR, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114(10):2149–2158. doi:10.1182/blood-2009-04-216671.
   PubMed Web of Science ®Google Scholar
• Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17(13):4232–4244. doi:10.1158/1078-0432.CCR-10-2660.
   PubMed Web of Science ®Google Scholar
• Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111–122. doi:10.1016/j.immuni.2007.05.016.
   PubMed Web of Science ®Google Scholar
• Tsushima F, Yao S, Shin T, Flies A, Flies S, Xu H, Tamada K, Pardoll DM, Chen L. Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood. 2007;110(1):180–185. doi:10.1182/blood-2006-11-060087.
   PubMed Web of Science ®Google Scholar
• Benson DM Jr., Bakan CE, Mishra A, Hofmeister CC, Efebera Y, Becknell B, Baiocchi RA, Zhang J, Yu J, Smith MK, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116(13):2286–2294. doi:10.1182/blood-2010-02-271874.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107(9):3639–3646. doi:10.1182/blood-2005-08-3376.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311–319. doi:10.1056/NEJMoa1411087.
   PubMed Web of Science ®Google Scholar
• Manson G, Herbaux C, Brice P, Bouabdallah K, Stamatoullas A, Schiano J-M, Ghesquieres H, Dercle L, Houot R. Prolonged remissions after anti-PD-1 discontinuation in patients with Hodgkin lymphoma. Blood. 2018;131(25):2856–2859. doi:10.1182/blood-2018-03-841262.
   PubMed Web of Science ®Google Scholar
• Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131(1):68–83. doi:10.1182/blood-2017-07-740993.
   PubMed Web of Science ®Google Scholar
• Chan TS, Khong PL, Kwong YL. Pembrolizumab for relapsed anaplastic large cell lymphoma after allogeneic haematopoietic stem cell transplantation: efficacy and safety. Ann Hematol. 2016;95(11):1913–1915. doi:10.1007/s00277-016-2764-1.
   PubMed Web of Science ®Google Scholar
• Rigaud C, Abbou S, Minard-Colin V, Geoerger B, Scoazec JY, Vassal G,  Jaff N, Heuberger L, Valteau-Couanet D, Brugieres L. Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma. Pediatr Blood Cancer. 2018;65(4). doi:10.1002/pbc.26902.
   Web of Science ®Google Scholar
• Hebart H, Lang P, Woessmann W. Nivolumab for refractory anaplastic large cell lymphoma: a case report. Ann Intern Med. 2016;165(8):607–608. doi:10.7326/L16-0037.
   PubMed Web of Science ®Google Scholar
• Song Y, Li Z, Xue W, Zhang M. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. Immuno. 2019;11(6):515–529. doi:10.2217/imt-2018-0173.
   Google Scholar
• Goodman AM, Piccioni D, Kato S, Boichard A, Wang H-Y, Frampton G, Lippman SM, Connelly C, Fabrizio D, Miller V, et al. Prevalence of PDL1 amplification and preliminary response to immune checkpoint blockade in solid tumors. JAMA Oncolo. 2018;4(9):1237–1244. doi:10.1001/jamaoncol.2018.1701.
   PubMed Web of Science ®Google Scholar
• da Silva PB, Real JM, Ferreira LRP, Esteves GH, Brito FDN, Baiocchi OCG. Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma. Hematol Oncol. 2018;36(4):709–712. doi:10.1002/hon.v36.4.
   PubMed Web of Science ®Google Scholar
• Kollmann D, Ignatova D, Jedamzik J, Chang Y-T, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, et al. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. Oncoimmunology. 2018;7(6):e1435226. doi:10.1080/2162402X.2018.1435226.
   PubMed Web of Science ®Google Scholar
• Kollmann D, Ignatova D, Jedamzik J, Chang Y-T, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, et al. Expression of programmed cell death protein 1 by tumor-infiltrating lymphocytes and tumor cells is associated with advanced tumor stage in patients with esophageal adenocarcinoma. Ann Surg Oncol. 2017;24(9):2698–2706. doi:10.1245/s10434-017-5858-7.
   PubMed Web of Science ®Google Scholar
• Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang Y-T, Lewik G, Schoppmann SF, Hoetzenecker W, Klepetko W, Guenova E, et al. PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer. Oncoimmunology. 2017;6(9):e1331194. doi:10.1080/2162402X.2017.1331194.
   PubMed Web of Science ®Google Scholar
• Taube JM, Young GD, McMiller TL, Chen S, Salas JT, Pritchard TS, Xu H, Meeker AK, Fan J, Cheadle C, et al. Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade. Clin Cancer Res. 2015;21(17):3969–3976. doi:10.1158/1078-0432.CCR-15-0244.
   PubMed Web of Science ®Google Scholar
• Grigg C, Rizvi NA. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? J Immunother Cancer. 2016;4(1):48. doi:10.1186/s40425-016-0153-x.
   PubMedGoogle Scholar
• Haque S, Yellu M, Randhawa J, Hashemi-Sadraei N. Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. Drug Des Devel Ther. 2017;11:2537–2549. doi:10.2147/DDDT.S119537.
   PubMed Web of Science ®Google Scholar
• Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and sezary’s syndrome. Ann Diagn Pathol. 2017;28:54–59. doi:10.1016/j.anndiagpath.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Cetinozman F, Jansen PM, Vermeer MH, Willemze R. Differential expression of programmed death-1 (PD-1) in sezary syndrome and mycosis fungoides. Arch Dermatol. 2012;148(12):1379–1385. doi:10.1001/archdermatol.2012.2089.
   PubMed Web of Science ®Google Scholar
• Samimi S, Benoit B, Evans K, Wherry EJ, Showe L, Wysocka M, Rook AH. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382–1388. doi:10.1001/archdermatol.2010.200.
   PubMedGoogle Scholar
• Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke C-D, Ortiz-Romero PL, Papadavid E, et al. European organisation for research and treatment of cancer consensus recommendations for the treatment of mycosis fungoides/sezary syndrome - update 2017. Eur J Cancer. 2017;77:57–74. doi:10.1016/j.ejca.2017.02.027.
   PubMed Web of Science ®Google Scholar
• Clark RA, Chong BF, Mirchandani N, Yamanaka K-I, Murphy GF, Dowgiert RK, Kupper TS. A novel method for the isolation of skin resident T cells from normal and diseased human skin. J Invest Dermatol. 2006;126(5):1059–1070. doi:10.1038/sj.jid.5700199.
   PubMed Web of Science ®Google Scholar
• Watanabe R, Gehad A, Yang C, Scott LL, Teague JE, Schlapbach C, Elco CP3, Huang V1, Matos TR4, Kupper TS, et al. Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med. 2015;7(279):279ra39. doi: 10.1126/scitranslmed.3010302.
   Web of Science ®Google Scholar
• Brooks AE. Skin-resident CD4+ T cells express NK receptors: lessons from skin pathologies. Cytometry A. 2014;85(10):827–829. doi:10.1002/cyto.a.v85.10.
   PubMedGoogle Scholar
• Bagot M, Moretta A, Sivori S, Biassoni R, Cantoni C, Bottino C, Boumsell L, Bensussan A. CD4(+) cutaneous T-cell lymphoma cells express the p140-killer cell immunoglobulin-like receptor. Blood. 2001;97(5):1388–1391. doi:10.1182/blood.V97.5.1388.
   PubMed Web of Science ®Google Scholar
• Sicard H, Bonnafous C, Morel A, Bagot M, Bensussan A, Marie-Cardine A. A novel targeted immunotherapy for CTCL is on its way: anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies. Oncoimmunology. 2015;4(9):e1022306. doi:10.1080/2162402X.2015.1022306.
   Web of Science ®Google Scholar
• Guenova E, Watanabe R, Teague JE, Desimone JA, Jiang Y, Dowlatshahi M, Schlapbach C, Schaekel K, Rook AH, Tawa M, et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res. 2013;19(14):3755–3763. doi:10.1158/1078-0432.CCR-12-3488.
   PubMed Web of Science ®Google Scholar
• Scarisbrick JJ, Hodak E, Bagot M, Stranzenbach R, Stadler R, Ortiz-Romero PL, Papadavid E, Evison F, Knobler R, Quaglino P, et al. Blood classification and blood response criteria in mycosis fungoides and sezary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. Eur J Cancer. 2018;93:47–56. doi:10.1016/j.ejca.2018.01.076.
   PubMed Web of Science ®Google Scholar
• Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015;125(18):2798–2805. doi:10.1182/blood-2014-07-590398.
   PubMed Web of Science ®Google Scholar
• Krejsgaard T, Lindahl LM, Mongan NP, Wasik MA, Litvinov IV, Iversen L, Langhoff E, Woetmann A, Odum N. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol. 2017;39(3):269–282. doi:10.1007/s00281-016-0594-9.
   PubMed Web of Science ®Google Scholar
• Nielsen M, Nissen MH, Gerwien J, Zocca M-B, Rasmussen HM, Nakajima K, Röpke C, Geisler C, Kaltoft K, Ødum N, et al. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated stat3. Blood. 2002;99(3):973–977. doi:10.1182/blood.V99.3.973.
   PubMed Web of Science ®Google Scholar
• Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013;14(12):1212–1218. doi:10.1038/ni.2762.
   PubMed Web of Science ®Google Scholar
• Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opin Investig Drugs. 2014;23(4):457–467. doi:10.1517/13543784.2014.876407.
   PubMed Web of Science ®Google Scholar
• Saulite I, Guenova E, Hoetzenecker W. Adverse reactions of antibody-therapy for primary cutaneous lymphomas: rituximab, brentuximab vedotin, alemtuzumab, and mogamulizumab. Curr Probl Dermatol. 2018;53:70–81.
   PubMedGoogle Scholar
• Bobrowicz M, Zagozdzon R, Domagala J, Vasconcelos-Berg R, Guenova E, Winiarska M. Monoclonal antibodies in dermatooncology-state of the art and future perspectives. Cancers (Basel). 2019;11(10):1420. doi:10.3390/cancers11101420.
   PubMed Web of Science ®Google Scholar
• DeSimone JA, Sodha P, Ignatova D, Dummer R, Cozzio A, Guenova E. Recent advances in primary cutaneous T-cell lymphoma. Curr Opin Oncol. 2015;27(2):128–133. doi:10.1097/CCO.0000000000000161.
   PubMed Web of Science ®Google Scholar
• Ramelyte E, Dummer R, Guenova E. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update. Expert Opin Investig Drugs. 2019;28(9):799–809. doi:10.1080/13543784.2019.1654995.
   PubMed Web of Science ®Google Scholar
• Rubio Gonzalez B, Zain J, Rosen ST, Querfeld C. Tumor microenvironment in mycosis fungoides and sezary syndrome. Curr Opin Oncol. 2016;28(1):88–96. doi:10.1097/CCO.0000000000000243.
   PubMed Web of Science ®Google Scholar
• Torrealba MP, Manfrere KC, Miyashiro DR, Lima JF, Oliveira M, Pereira NZ, Cury-Martins J, Pereira J, Duarte AJS, Sato MN, et al. Chronic activation profile of circulating CD8+ T cells in Sézary syndrome. Oncotarget. 2018;9(3):3497–3506. doi:10.18632/oncotarget.v9i3.
   PubMedGoogle Scholar
• Querfeld C, Leung S, Myskowski PL, Curran SA, Goldman DA, Heller G, Wu X, Kil SH, Sharma S, Finn KJ, et al. Primary T cells from cutaneous T-cell lymphoma skin explants display an exhausted immune checkpoint profile. Cancer Immunol Res. 2018;6(8):900–909. doi:10.1158/2326-6066.CIR-17-0270.
   PubMed Web of Science ®Google Scholar
• Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJA, Hobo W, Gorecka MA, de Haan AFJ, Mulders P, Punt CJA, et al. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012;35(2):169–178. doi:10.1097/CJI.0b013e318247a4e7.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhu X, Xu Y, Zhang D, Li Y, Tao Y, Piao H, Li D, Du M. Programmed cell death-1 (PD-1) and T-cell immunoglobulin mucin-3 (Tim-3) regulate CD4+ T cells to induce type 2 helper T cell (Th2) bias at the maternal-fetal interface. Hum Reprod. 2016;31(4):700–711. doi:10.1093/humrep/dew019.
   PubMed Web of Science ®Google Scholar
• Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36(4):265–276. doi:10.1016/j.it.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Armand P. Immune checkpoint blockade in hematologic malignancies. Blood. 2015;125(22):3393–3400. doi:10.1182/blood-2015-02-567453.
   PubMed Web of Science ®Google Scholar
• Anzengruber F, Ignatova D, Schlaepfer T, Chang Y-T, French LE, Pascolo S, Contassot E, Bobrowicz M, Hoetzenecker W, Guenova E, et al. Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in sezary syndrome. Leuk Lymphoma. 2019;60(8):1899–1907. doi:10.1080/10428194.2018.1564827.
   PubMed Web of Science ®Google Scholar
• Khodadoust MS, Rook A, Porcu P, Foss FM, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N et al. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome: A Multicenter Phase II Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2020; 38:20–8. doi:10.1200/JCO.19.01056.
   Google Scholar
• Wada DA, Wilcox RA, Harrington SM, Kwon ED, Ansell SM, Comfere NI. Programmed death 1 is expressed in cutaneous infiltrates of mycosis fungoides and sezary syndrome. Am J Hematol. 2011;86(3):325–327. doi:10.1002/ajh.v86.3.
   PubMed Web of Science ®Google Scholar
• Carney DN, Bunn PA Jr., Schechter GP, Gazdar AF. Lymphocyte transformation in patients with cutaneous T-cell lymphomas. Int J Cancer. 1980;26:535–542. doi:10.1002/ijc.2910260503.
   PubMed Web of Science ®Google Scholar
• Meech SJ, Edelson R, Walsh P, Norris DA, Duke RC. Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941:46–58. doi:10.1111/j.1749-6632.2001.tb03710.x.
   PubMed Web of Science ®Google Scholar
• Kantekure K, Yang Y, Raghunath P, Schaffer A, Woetmann A, Zhang Q, Odum N, Wasik M. Expression patterns of the immunosuppressive proteins PD-1/CD279 and PD-L1/CD274 at different stages of cutaneous T-cell lymphoma/mycosis fungoides. Am J Dermatopathol. 2012;34(1):126–128. doi:10.1097/DAD.0b013e31821c35cb.
   PubMed Web of Science ®Google Scholar
• Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco C, Lee N, Juneja V, Zhan Q, et al. Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162(6):1242–1256. doi:10.1016/j.cell.2015.08.052.
   PubMed Web of Science ®Google Scholar
• Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76(23):6964–6974. doi:10.1158/0008-5472.CAN-16-0258.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, et al. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015;126(3):328–335. doi:10.1182/blood-2015-02-629543.
   PubMed Web of Science ®Google Scholar
• Guenova E, Metzler G, Hoetzenecker W, Berneburg M, Rocken M. Classic mediterranean kaposi’s sarcoma regression with sirolimus treatment. Arch Dermatol. 2008;144(5):692–693. doi:10.1001/archderm.144.5.692.
   PubMedGoogle Scholar
• Nguyen LT, Ohashi PS. Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunolo. 2015;15(1):45–56. doi:10.1038/nri3790.
   PubMed Web of Science ®Google Scholar
• Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–5074. doi:10.1158/1078-0432.CCR-13-3271.
   PubMed Web of Science ®Google Scholar
• Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The “cancer immunogram”. Science. 2016;352(6286):658–660. doi:10.1126/science.aaf2834.
   PubMed Web of Science ®Google Scholar
• Wartewig T, Kurgyis Z, Keppler S, Pechloff K, Hameister E, Öllinger R, Maresch R, Buch T, Steiger K, Winter C, et al. PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017;552(7683):121–125. doi:10.1038/nature24649.
   PubMed Web of Science ®Google Scholar
• Zheng YJ, Lee A, Pincus L, Ho W, Vujic M, Ortiz-Urda S. Cutaneous CD56(+) T-cell lymphoma developing during pembrolizumab treatment for metastatic melanoma. JAAD Case Rep. 2018;4(6):540–542. doi:10.1016/j.jdcr.2018.01.016.
   PubMedGoogle Scholar
• Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL. PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol. 2007;37:2405–2410. doi:10.1002/eji.200737461.
   PubMed Web of Science ®Google Scholar
• Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014;38(12):1715–1723. doi:10.1097/PAS.0000000000000297.
   PubMed Web of Science ®Google Scholar
• Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res. 2017;23(12):3158–3167. doi:10.1158/1078-0432.CCR-16-1761.
   PubMed Web of Science ®Google Scholar
• Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 2018;8(9):1156–1175. doi:10.1158/2159-8290.CD-17-1033.
   PubMed Web of Science ®Google Scholar